Endothelial cells (ECs) 
Introduction
Cancer results from the concerted action of malignant cells interacting with the many cellular and protein components of the tumor stroma 1 . Different strategies to therapeutically target the tumor stroma are currently being pursued. Most notably, drugs targeting endothelial cells (ECs) of the angiogenic tumor vasculature have been introduced into clinical practice following successful preclinical and clinical trials 2 . Despite abundant evidence that angiogenesis is instrumental for the growth of solid tumors, the clinical benefit from drugs incorporating antiangiogenic activity have thus far proved limited, typically improving progression-free survival by 2-6 months with only minimal benefit in terms of overall survival 3 . In addition, recent preclinical studies suggest that tumors can acquire resistance to blockade of angiogenic growth factors, and as a consequence attain an increased invasive and metastatic potential 4, 5 . Evidently, we must learn more about the biology underlying the positive effects of targeted anti-vascular therapies in order to more accurately be able to predict in which context to use a particular drug, as well as which patients will benefit the most from treatment.
Endothelial cells in small blood vessels and capillaries interact with pericytes, cells of mesenchymal origin that provide important support for blood vessel formation and function 6 .
Numerous studies describe the significance of members of the platelet-derived growth factor (PDGF) family for recruitment to and productive association of pericytes with the blood vessel endothelium during embryonal development 7 . Strikingly, mice lacking components of the PDGF-B/PDGFR-β signaling axis are essentially devoid of pericytes, and as a consequence die from microhemorrhaging due to malformed blood vessels. The importance of PDGF signaling for pericytes in tumor blood vessels is further illustrated by recent work. Studies of genetically
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From [4] manipulated mice demonstrate the significance of endothelium-derived PDGF-BB for a normal integration of pericytes into tumor blood vessels 8 . In addition, ectopic expression of PDGF-BB by tumor cells results in increased recruitment of mural cells to blood vessels upon establishment of subcutaneous tumors, whereas inhibition of PDGFR signaling decreases the extent of pericyte coverage in tumors [9] [10] [11] [12] . The notion of targeting pericyte function, e.g. via their PDGF receptors, to gain enhanced efficacy of anti-angiogenic treatment regimens is supported by reports of beneficial effects of combining PDGFR inhibitors with anti-angiogenic drugs or regimens [11] [12] [13] [14] [15] .
However, despite the tight physical and functional association between ECs and pericytes, there is an evident paucity of information about the signals exchanged between the two cell types.
Herein, we have delineated a molecular mechanism involved in conferring pericyte-dependent For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From [ 
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Materials and Methods
Mice, tumors and treatments. All animal studies described were approved by the Karolinska Instituet committee for animal care, application N146/08. RIP1-Tag2 mice were treated with imatinib (Glivec/Gleevec, Novartis, 150 mg/kg and day divided in a morning dose of 50 mg/kg and an afternoon dose of 100 mg/kg) dissolved in PBS, or with CP-673,451 (Pfizer, 50 mg/kg and day) dissolved in PEG-400 for 5 consecutive days by gavage at 12 weeks of age. C57Bl/6 mice were subcutaneously injected with 10 6 cells of the following tumor cell lines: B16 [7] using Quantitect primer assays (Qiagen, Hilden, Germany) with L19 as universal reference genes. Transcript levels were expressed as % of L19 using the formula:
Immunostaining. Following heart perfusion with PBS and 4% paraformaldehyde, tumors were excised and embedded in Optimal Cutting Temperature freezing medium. Tissue sections were air dried, post-fixed with ice cold acetone for 10 min, and blocked using serum-free protein block (DAKO, Glostrup, Denmark) for 60 min at rt. Next immunostaining was performed using the following primary antibodies: CD31 (1 μ g/ml, #553370, BD Pharmingen, Franklin Lakes, In situ hybridization. Double in situ hybridization was used to detect mRNA for VEGF-A and for Flk1 (used as an EC marker) on RIP1-Tag2 frozen tumor samples. The protocol was adapted from 16, 17 . Oligonucleotide probes complementary to VEGF-A and Flk1 were used (1μg/ml).
The VEGF-A probe was biotinylated and further detected by using streptavidin conjugated to Alexa 594 (Invitrogen, Carlsbad, CA). The Flk1 probe was FITC-labeled. The probes in forward orientation were used as negative controls and gave no specific signal (data not shown).
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From [ 
8]
Microscope image acquisition
Imaging was performed using a Nikon Eclipse E800 microscope equipped with Nikon Plan Fluor objectives (10x, NA 0.30; 20x, NA 0.50; 40x, NA 0.75) at rt in air using Alexa 594-and Alexa 488-coupled secondary antibodies. Images were acquired using a SPOT RTKE camera using the SPOT advanced software. 
Western blotting. MS1 cells sorted from mono-or co-cultures with HBVP were lysed in 20 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 0.5% deoxycholic acid, and 0.5% Triton X-100
containing Complete protease inhibitor (Roche Applied Science, Penzberg, Germany). Thirty μ g of protein was loaded onto SDS-PAGE gels (Invitrogen, Carlsbad, CA), and subsequently transferred onto a nitrocellulose membrane using the iBlot system (Invotrogen, Carlsbad, CA).
Western blotting was performed using antibodies against Bcl-w (AB1723, 5μg/ml, Chemicon, Billerica, MA) and VEGF-A (MAB493, 1μg/ml, R&D Systems, Minneapolis, MN) with β -actin (GTX26276, 1:5000, GeneTex, Irvine, CA) serving as loading control.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From [11] Statistical analysis. Data are shown as mean ± standard error of the mean. Statistical analysis was performed using an un-paired, two-tailed Student's t-test with α =0.05. PNET from RIP1-Tag2 mice treated or not with imatinib (EC control and EC imatinib , respectively).
Results
Pharmacological
We focused our study on genes with a documented role in cell survival and specifically assessed Taken together, detachment of pericytes from tumor ECs by the use of two different pharmacological inhibitors lead to decreased EC expression of Bcl-w, suggesting a role for Bclw in promoting EC survival. To address the hypothesis that Bcl-w acts as an anti-apoptotic factor in ECs, we transfected MS1 mouse pancreatic islet ECs with siRNA targeting Bcl-w and assessed EC apoptosis and viability upon treatment with vinblastine, a drug known to produce cytotoxic effects on ECs both in vitro and in vivo [22] [23] [24] . While knock-down of Bcl-w did not change the growth rate ( Figure 2D ) or apoptotic rate (Supplemental figure 1C; For Figure 2A) . Immunostaining demonstrated readily detectable levels of Bcl-w protein within the cultured ECs, both in monoculture and in co-culture with pericytes, indicating that pericyte association is not needed to [16] maintain basal levels of Bcl-w expression in ECs (Supplemental Figure 2B) . After four days of co-culture, the MS1 cells were separated from HBVP by FACS and the expression of prosurvival genes compared to MS1 cells purified from mono-cultures was assessed. In close agreement with the findings in tumors in vivo, the presence of pericytes produced a significant upregulation of Bcl-w and VEGF-A in ECs (Figure 4A-B) . Importantly, VEGF-A and Bcl-w were also increased at the protein level in ECs following co-culture with HBVP ( Figure 4C ).
Using a transwell co-culture system, we assessed the need for physical contact for the pericyte- Figure 4E ).
Taken together, our observations from studies using a newly established co-culture system of ECs and pericytes confirm that mural cells confer a survival advantage to ECs through regulation of autocrine VEGF-A signaling and Bcl-w expression.
Pericyte-induced survival signaling in ECs is mediated by NF-κB. Next, to gain insight into the mediators involved in inducing VEGF-A and Bcl-w in ECs as a result of pericyte contact, we took a candidate approach. Since hypoxia is a strong inducer of VEGF-A, we analyzed the expression of other hypoxia-regulated genes, including Glut1, by quantitative RT-PCR. tumor ECs leading to enhanced survival, as elucidated by our work, is shown in Figure 7 .
However, no change in the expression of genes related to hypoxia was observed in ECs isolated
20]
Discussion
Despite the tight association between the two cell types, little is known about the molecular nature of the crosstalk engaging pericytes and ECs during tissue homeostasis or neoangiogenesis. Newly formed vascular sprouts recruit pericytes primarily through secretion of PDGF-BB by endothelial tip cells 32 . Pericytes respond by migrating along the matrix-retained gradient of PDGF-BB, and by a proliferative burst as they reach the tip of the sprout 32, 33 .
Reciprocally, pericytes upregulate expression of cell-bound VEGF-A as they mature and are recruited into newly formed vessels 26 . We found that pericytes, in addition to producing VEGF-A that acts in a paracrine fashion, stimulate autocrine expression of VEGF-A by tumor ECs, suggesting that the two different mechanisms for pericyte-dependent VEGF-A stimulation of ECs are functionally distinct. In agreement with this notion, mice harboring conditional ablation of Vegfa in ECs exhibit progressive endothelial degeneration despite normal levels of exogenously derived VEGF-A 25 . Recently, EC expression of VEGF-A was found to be regulated in an integrin α 3 β 1 -dependent manner, implying that the composition of the vascular basement membrane modulates the phenotype of ECs 34 . Similarly, we demonstrate here that blockade of integrin α v abolishes pericyte-induced control of autocrine VEGF-A and survival in tumor ECs. In the context of vascular maturation, it is interesting to note that the recruitment of pericytes to angiogenic sprouts is closely correlated to enhanced basement membrane production 35 . We found that pericytes need to be in apposition to ECs in order to confer induction of VEGF-A and Bcl-w, possibly because of the requirement to deposit basement membrane products within close range of the EC. However, it may be that actual physical contact between pericytes and ECs is not needed in the context of tumor angiogenesis, as it has been noted that pericytes in malignant tissues are only loosely attached to the vasculature 36 .
[21]
More work is needed to conclusively identify the ligand(s) responsible for integrin α v ligation, but pericytes abundantly and selectively expressed vitronectin in the tumor models employed in our studies. Interestingly, adhesion of ECs to vitronectin through integrin α v β 3 protects from apoptosis in an NF-κB dependent manner 30, 31 , in strong concordance with our observation that pericyte association governs the transcriptional activity of direct NF-κB targets, including VEGF-A, in tumor ECs in vivo 27, 28 . Thus, by tying together previous independent observations of regulation of EC survival by vitronectin, integrin α v β 3 , NF-κB, and autocrine VEGF-A, we identify pericytes as key orchestrators of tumor EC survival by triggering EC-matrix interactions.
Stimulation of ECs by extracellularly provided VEGF-A leads to the production of several antiangiogenic signaling proteins in parallel, including Bcl-2, survivin and XIAP 37,38 ( Figure 7 ). The primary cell-autonomous function of VEGF-A in ECs is thought to be promotion of survival, although the molecular mechanism has not been fully explored 25 . We provide evidence that autocrine VEGF-A sustained by pericytes leads to induction of the anti-apoptotic protein Bcl-w.
Thus, survival signaling in ECs occurring in response to paracrine and autocrine stimulation with VEGF-A appears to be mediated through distinct downstream pathways, the identity of which should be the topic for further studies. Mice deficient for Bcl-w do not display any overt vascular abnormalities, and are alive and fertile 39 . Whether the lack of Bcl-w in the knock-out mice sensitizes ECs to the action of anti-angiogenic therapies, or whether regulation of other Bclfamily members compensates for the lack of Bcl-w in ECs, deserves renewed attention in light of our findings.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From [22] Vascular regression following exposure to hyperoxia leads to a selective ablation of immature, non-pericyte covered capillaries 40 . Furthermore, several studies demonstrate detrimental effects of pericyte targeting through the use of PDGFR inhibitors on tumor EC survival in the face of anti-angiogenic treatment regimens, resulting in therapeutic synergy [11] [12] [13] [14] [15] . Indeed, combined treatment of RIP1-Tag2 mice with imatinib and metronomic, anti-angiogenic chemotherapy results in a significant increase in tumor EC apoptosis 11 . In addition to conferring protection from apoptosis to ECs, pericytes also control EC proliferation. Thus, ectopic expression of 34, 43 . Further studies to investigate whether modulation of pericyte recruitment or function can be used as a strategy to modify EC behavior during various pathological settings, including ischemic disease and retinopathy are warranted. In this context it is important to note that the description of pericyte-dependent effects on the EC phenotype may vary depending on whether a pharmacological or genetic approach is taken to reduce pericyte coverage of blood vessels; pharmacological agents may have off-target effects or produce incomplete functional ablation, whereas germ line genetic defects may be subject to compensatory adaptations during embryogenesis.
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From [23] To avoid the risk of inducing compensatory survival pathways in ECs, we chose to use pharmacological tools to diminish pericyte association, with the corollary objective to gain additional insight into the clinical use of drugs incorporating inhibitory action against the PDGF and/or the VEGF system. Anti-angiogenic agents targeting VEGF/VEGFR signaling, including bevacizumab, sunitinib and sorafenib, have made their way into the clinic during recent years.
Sunitinib and sorafenib are small molecule VEGFR inhibitors that include inhibitory action against PDGFR, thus encompassing dual pericyte and EC targeting capabilities in a single drug.
The pre-clinical data presented herein, indicating that pericytes protect tumor ECs from apoptosis through induction of an autocrine VEGF-A signaling loop, lead to the prediction that inhibitors of the VEGF pathway acting intracellularly, such as sunitinib and sorafenib, would be superior to antibody therapy by bevacizumab, which acts exclusively on paracrine VEGF-A signaling. Nevertheless, the efficacies of bevacizumab, sunitinib and sorafenib are comparable in terms of prolongation of progression-free survival in renal cell carcinoma patients [44] [45] [46] . It may be that off-target effects of the more broadly acting ATP-competitive small molecules mandate that they be dosed in a sub-optimal manner, thus giving rise to incomplete inhibition of VEGF signaling, whereas administration of an antibody with complete specificity for blockade of VEGF-A would result in a higher degree of signal inhibition. Thus, a treatment regimen combining inhibition of pericyte and EC function through the use of concomitant administration of a VEGF-targeting antibody and a PDGF-BB/PDGFRβ-targeting antibody may hold promise for improved efficacy by blocking both paracrine and autocrine VEGF signaling in ECs. In addition, our studies identify inhibition of NF-κB and Bcl-w as new approaches to improve antivascular therapy in malignant disease by interfering with specific aspects of EC-pericyte crosstalk. Given the recent pre-clinical reports of acquired resistance leading to increased [33] of both intra-and extra-cellularly acting VEGFR inhibitors (AG-028262 and sFlt1, respectively), whereas the pericyte-induced autocrine signaling by VEGF-A is only sensitive to intra-cellularly acting inhibitors.
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